Eva Martinez-Balibrea
Eva Martinez-Balibrea
principal investigator at Catalan Instiute of Oncology (ICO) and Health sciences research institute
Verified email at
Cited by
Cited by
Tumor-related molecular mechanisms of oxaliplatin resistance
E Martinez-Balibrea, A Martínez-Cardús, A Ginés, V Ruiz de Porras, ...
Molecular cancer therapeutics 14 (8), 1767-1776, 2015
Resistant mechanisms to BRAF inhibitors in melanoma
JL Manzano, L Layos, C Bugés, M de los Llanos Gil, L Vila, ...
Annals of translational medicine 4 (12), 2016
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis
D Rosmarin, C Palles, D Church, E Domingo, A Jones, E Johnstone, ...
Journal of Clinical Oncology 32 (10), 1031, 2014
ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and …
M Yin, J Yan, E Martinez-Balibrea, F Graziano, HJ Lenz, HJ Kim, J Robert, ...
Clinical cancer research 17 (6), 1632-1640, 2011
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
E Martinez-Balibrea, A Abad, A Martínez-Cardús, A Ginés, M Valladares, ...
British journal of cancer 103 (4), 581-589, 2010
Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway
V Ruiz de Porras, S Bystrup, A Martínez-Cardús, R Pluvinet, L Sumoy, ...
Scientific reports 6 (1), 24675, 2016
CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer
S Cabrero-de Las Heras, E Martínez-Balibrea
World journal of gastroenterology 24 (42), 4738, 2018
Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer
C Moutinho, A Martinez-Cardús, C Santos, V Navarro-Pérez, ...
Journal of the national cancer institute 106 (1), djt322, 2014
A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect
P Lopez-Serra, M Marcilla, A Villanueva, A Ramos-Fernandez, A Palau, ...
Nature communications 5 (1), 3608, 2014
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer
E Martinez-Balibrea, A Abad, E Aranda, J Sastre, JL Manzano, ...
European Journal of Cancer 44 (9), 1229-1237, 2008
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1 …
RR Font A1, Sánchez JM, Tarón M, Martinez-Balibrea E, Sánchez JJ, Manzano JL ...
Investigational new drugs 21 (4), 435-443, 2003
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1 …
A Font, JM Sánchez, M Tarón, E Martinez-Balibrea, JJ Sánchez, ...
Investigational new drugs 21, 435-443, 2003
A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines
E Martinez-Balibrea, C Plasencia, A Ginés, A Martinez-Cardús, ...
Molecular cancer therapeutics 8 (4), 771-778, 2009
Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells
C Plasencia, E Martinez-Balibrea, A Martinez-Cardus, DI Quinn, A Abad, ...
International journal of oncology 29 (1), 225-235, 2006
Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin‐based chemotherapy
E Martinez‐Balibrea, A Martínez‐Cardús, E Musulén, A Ginés, ...
International journal of cancer 124 (12), 2905-2910, 2009
Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer
A Martinez-Cardus, E Martinez-Balibrea, E Bandres, R Malumbres, ...
Molecular cancer therapeutics 8 (1), 194-202, 2009
Hypoxia: the cornerstone of glioblastoma
M Domènech, A Hernández, A Plaja, E Martínez-Balibrea, C Balañà
International journal of molecular sciences 22 (22), 12608, 2021
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
J Codony-Servat, M Cuatrecasas, E Asensio, C Montironi, ...
British journal of cancer 117 (12), 1777-1786, 2017
Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells
S Gonçalves-Ribeiro, NG Díaz-Maroto, M Berdiel-Acer, A Soriano, ...
Oncotarget 7 (37), 59766, 2016
Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic …
E Martinez-Balibrea, JL Manzano, A Martinez-Cardus, T Moran, ...
Oncology reports 17 (3), 637-645, 2007
The system can't perform the operation now. Try again later.
Articles 1–20